トラスツズマブを併用した腫瘍溶解性レオウイルスはヒトHER2陽性胃癌細胞においてTRAILシグナルを介して抗腫瘍効果を増強する<要約> by Shingo Hamano
  
Nagoya City University Academic Repository 
 
 
 
学 位 の 種 類 
 
 
  博士 (医学) 
 
報 告 番 号 
 
  甲第１４６６号 
 
学 位 記 番 号   第１０５２号 
 
氏    名 
 
 
  濵野 真吾 
 
 
授 与 年 月 日 
 
 
  平成 27 年 3 月 25 日 
 
 
 
 
 
学位論文の題名 
 
 
 
 
 
Oncolytic reovirus combined with trastuzumab enhances antitumor 
efficacy through TRAIL signaling in human HER2-positive gastric 
cancer cells 
(トラスツズマブを併用した腫瘍溶解性レオウイルスはヒト HER2 陽性胃癌
細胞において TRAIL シグナルを介して抗腫瘍効果を増強する) 
 
Cancer Letters. Vol.356：P.846-854,2015 
 
 
 
 
論文審査担当者 
 
 
  主査： 浅井 清文 
  副査： 竹山 廣光, 城 卓志 
 
 
Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through 
TRAIL signaling in human HER2-positive gastric cancer cells 
 
BACKGROUND： 
Human epidermal growth factor receptor 2 (HER2) overexpression and amplification 
have been detected in 10% to 20% of gastric cancers and are associated with a poor 
outcome. The HER2-targeting agent, trastuzumab, is effective for HER2-overexpressing 
gastric cancer therapy. As oncolytic reovirus is currently undergoing clinical trials 
internationally, we wanted to explore whether the combination therapy using 
trastuzumab and reovirus might provide a novel, more effective therapeutic option for 
gastric cancer.  
 
METHODS: 
Cell proliferation and cell apoptosis were examined in vitro, while molecular analysis of 
pathways responsible for cell damage was examined using polymerase chain reaction 
array. Activation of the proteins related to apoptosis, cell growth and survival was 
detected by Western blotting. Mouse tumor xenograft models were used to examine 
antitumor activity in vivo.  
 
RESULTS: 
Both in vitro and in vivo studies provided evidence that the combination therapy is a 
more powerful modality against HER2-overexpressing gastric cancer cells than 
treatment using a single agent. Molecular analysis indicated that the combination 
therapy induced significantly higher levels of tumor necrosis factor related 
apoptosis-inducing ligand (TRAIL) in cancer cells. Antibody against TRAIL strongly 
inhibited cell toxicity caused by the combined treatment.  
 
CONCLUSIONS: 
These results suggest that reovirus may augment trastuzumab-induced cytotoxicity in 
gastric cancer cells. 
 
 
